Abstract: A method for delivering a biologically active substance including the steps of: (a) combining said biologically active substance with a macromer; (b) forming a mixture of the combination formed in step (a); (c) polymerizing said mixture to form articles; and (d) administering said articles, or a portion thereof, to a mammal, where step (c) takes place in the absence of a polymerizable monovinyl monomer, is disclosed.

Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Abstract: The present invention relates to a titratable dosage transdermal delivery system for systemic delivery of a therapeutic agent or drug. The system comprises a plurality of patch units that are connected along one or more borders. The plurality of patch units are divisible into units along the one or more borders having one or more lines of separation. Each patch unit is surrounded by a border. The therapeutic patch has at least a backing layer and a therapeutic agent comprising layer. The dosage of therapeutic agent delivered to a patient is proportional to the number of patch unit applied per treatment. The system enables systemic administration of a titratable dosage of therapeutic agent, adjustable by the patient under the direction of a physician, through the skin or mucosa. Moreover, the invention relates to a method of making the titratable dosage transdermal delivery system.

Abstract: Processes for manufacturing a low-substituted hydroxypropyl cellulose are described that include dipping pulp into an alkaline solution to prepare an alkali cellulose, reacting the alkali cellulose with a hydroxypropylating agent to yield a product in a complete dissolution state, dissolving completely the product in an aqueous medium to provide a product in a complete dissolution state, neutralizing with an acid to yield a precipitate, washing, drying, and pulverizing to yield a powder having a volume-average particle diameter of less than 25 microns which is determined by a dry laser diffraction method, a loose bulk density of 0.29 g/ml or more and less than 0.40 g/ml, and a tapped bulk density of 0.55 g/ml or more. Low-substituted hydroxypropyl celluloses are also described.

Abstract: A topical patch having non-steroid antirheumatic agent as active substance, consisting of a backing layer inert to the active substance, a self-adhesive, active substance-containing matrix layer based on a polyacrylate adhesive, and a protective film to be removed prior to use, is characterized in that a. the non-steroid antirheumatic agent has a free carboxyl group, b. the active substance-containing matrix of the patch consists of a polyacrylate adhesive cross-linked with multivalent metal ions and having free carboxyl groups, and is free of hydroxyl groups, c. the matrix contains a fatty acid as plasticizer and permeation enhancer, and d. the backing layer consists of a material that is elastic in at least one direction.

Abstract: The invention relates to the use of cinnamic acid, or of at least one of its derivatives, in a cosmetic composition as an agent for promoting the synthesis of the skin's total lipids. The invention also relates to a cosmetic composition comprising an effective amount of cinnamic acid or of at least one of its derivatives.

Abstract: A preferred embodiment of the device of the invention, which is adapted to be applied circumferentially about a phallus, having a perimeter, and to facilitate intracavernosal anesthesia, generally comprises: a strip having a length at least slightly greater than the perimeter of the phallus, and a first end and a second end; and a hook and loop closure for releasably fixing at least a portion of the strip proximate the first end to a second portion of the strip

Abstract: A method of manufacturing ammonium quat-containing raw material composition with improved transportation efficiency and/or processing properties is provided, including the step of forming a mixture containing the ammonium quat in a solvent that includes at least one glycol and at least one fatty alcohol, wherein said raw material composition has cationic activity of over 35%.

Abstract: The invention relates to a method for increasing the concentration of the cis-9, trans-11 isomer of octadecadienoic acid in the milk fat and/or the tissue fat of a ruminant. In the method the ruminant is fed the trans-11 isomer of octadecenoic acid either as such or mixed with other feed, separately or together with other fatty acids.

Abstract: The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.

Abstract: A water-based, quick-drying, gel-type disinfectant composition comprising one of more anti-microbicidal ingredients, 0-30% of an alcohol, a thickening agent, an emulsifier, and water. The composition is especially relevant for use as a hand or skin disinfectant to be used in the food industry or in hospitals. The thickening agent is a crucial part of the composition and is typically selected from acrylic acid copolymers, methacrylic acid copolymers, sodium carboxycellulose, hydroxyethylcellulose, and hydroxypropylcellulose. A typical composition comprises 0.05-5.0% of a fatty alcohol-polyglycol ether as an emulsifier, 0.5-5.0% of glycerin, 0.01-2.0% of one of more additives including 0.05-1.0% of a basic compound, and substantially the balance of water.

Abstract: Film coatings for enteric and colonic release at selected pH are provided by selecting and/or formulating a shellac of a predetermined acid number. The method includes the selection of the acid number to provide the release at the specified pH and a method of providing a shellac of a predetermined acid number by blending of shellacs of different acid numbers. In general, films that release or dissolve at or above pH 7.4 are based on the selection of shellac with an acid number below 74. Films that release or dissolve above pH 7.0 are comprised of shellac selected with an acid number below 80. Films that release or dissolve at below pH 7.0 are comprised of shellac selected to have an acid number above 80. The film coating may be modified with a water soluble resin and/or a plasticizer. Preferably the shellac will comprise 50% or more of the resin system, and is formed out of water, not alcohol.

Abstract: A liquid pharmaceutical for oral delivery wherein at the time of use, a solid unit dosage form is added to the liquid wherein the unit dosage form is comprised of a substrate soluble in the liquid and a particulate pharmaceutically active material in a pharmaceutically effective amount. At the time of use, the unit dosage form is added to the liquid, without requiring measurement of the liquid, and the entire liquid is consumed to provide for oral delivery of the pharmaceutically effective amount of material.

Abstract: The invention relates to a commercially feasible fatty ammonium quat compound or composition useful in hair products and the like comprising the properties of being flakeable and having at least 35% cationic activity.

Abstract: A stannous fluoride composition is disclosed. The composition comprises stannous fluoride and at least one zinc containing compound. The zinc containing compounds stabilize and prevent hydrolysis of the stannous ions resulting in a stannous fluoride composition for use in the treatment of epidermal irritations and infections.

Abstract: The subject invention pertains to novel materials and methods for use in treating patients afflicted with oncological disorders, such as tumors. One aspect of the invention concerns methods for treating tumors comprising the administration of drug loaded pH-sensitive microspheres to a patient in need of anticancer therapy. The pH-sensitive microspheres have a swelling transition with the pH range found in or near tumor tissue. When the microspheres swell, the loaded drug is released into the microenvironment of the tumor tissue. The subject invention also pertains to novel microspheres useful in the methods of the invention. The microspheres are capable of effectively releasing a loaded substance at a pre-determined pH. The subject invention also concerns novel methods for synthesizing the microspheres of the present invention.

Abstract: The invention concerns the use of sophorolipids in lactone form comprising a major part of diacetyl lactones as agent for stimulating skin dermal fibroblast cell metabolism and more particularly as agent for stimulating collagen neosynthesis, at a concentration of 0.01 ppm at 5% (p/p) of dry matter in formulation. The invention is applicable in cosmetology and dermatology.

Abstract: The development of oviparous species such as birds after hatch is enhanced by feeding a subject prior to hatch. The subject is fed with a nutrient composition and/or an enteric modulator. A preferred nutrient composition contains at least one protein, peptide, amino acid or carbohydrate; a preferred enteric modulator is hydroxymethylbutyrate. Feeding may be accomplished by administering the nutrient composition and/or enteric modulator into the amnion where it is then orally ingested by the subject.

Abstract: Devices, methods, and compositions for vaginal delivery of bisphosphonates. A targeted site delivery of bisphosphonates to the vagina using a medicated intravaginal device comprising a bisphosphonate composition formulated for transvaginal delivery. A method for treatment of osteoporosis and related bone and skeleton diseases, for prevention of bone breakdown and loss of bone mass and strength by intravaginal administration of bisphosphonates to the vagina and transvaginal delivery of bisphosphonates to the general circulation.

Abstract: The invention relates to a process for the production of morphologically uniform microcapsules that contain peptides, proteins or other water-soluble biologically active substances as active ingredients as well as microcapsules that are produced according to this process with a degree of concentration of between 3 to 30% by weight and a diameter ≦8 &mgr;m. According to the invention, biodegradable polymers are dissolved in a halogen-free solvent or solvent mixture, and the buffered active ingredient solution, which has a pH of between 6.0 to 8.0, is dispersed into this solution. Then, an aqueous solution that contains a surfactant (W/O/W-emulsion) is added to this W/O-emulsion, and the solvent is removed. The microcapsules that are produced with this process do not show any tendency toward agglomeration. The encapsulation efficiency of the process is approximately 90 to 95%.